Business
Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022
WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its fourth quarter and year-end 2021 financial results on Tuesday, March 1, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, March 1, to discuss the Company's financial results and provide a general business update.\nThe live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:\nConference ID: 4019975Domestic Dial-in Number: (855) 251-6663International Dial-in Number: (281) 542-4259Live webcast: https://edge.media-server.com/mmc/p/pqahpntn\nFor those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.\nAbout Syndax Pharmaceuticals, Inc.\nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. \nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] 212.600.1902\nMedia ContactBenjamin [email protected] 862.368.4464\nSNDX-G\n View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2021-financial-results-and-host-conference-call-and-webcast-on-march-1-2022-301486124.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":4323,"tagName":"div"}]